These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 6163740)
1. Cholecystokinin (pancreozymin). Synthesis and properties of the N alpha-acetyl-derivative of cholecystokinin 27-33. Bodanszky M; Tolle JC; Gardner JD; Walker MD; Mutt V Int J Pept Protein Res; 1980 Nov; 16(5):402-11. PubMed ID: 6163740 [TBL] [Abstract][Full Text] [Related]
2. Cholecystokinin (pancreozymin). 4. Synthesis and properties of a biologically active analogue of the C-terminal heptapeptide with epsilon-hydroxynorleucine sulfate replacing tyrosine sulfate. Bodanszky M; Martinez J; Priestley GP; Gardner JD; Mutt V J Med Chem; 1978 Oct; 21(10):1030-5. PubMed ID: 722712 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and some pharmacological properties of Z-Tyr(SO3H)-Met-Gly-Trp-Met-Asp(Phe-NH2)-OH, a 32-beta-aspartyl analogue of cholecystokinin (pancreozymin) 27-33. Martinez J; Winternitz F; Bodanszky M; Gardner JD; Walker MD; Mutt V J Med Chem; 1982 May; 25(5):589-93. PubMed ID: 6177857 [TBL] [Abstract][Full Text] [Related]
4. N-terminal fragments of CCK-(26-33) as cholecystokinin receptor antagonists in guinea pig pancreatic acini. Gardner JD; Knight M; Sutliff VE; Jensen RT Am J Physiol; 1985 Jan; 248(1 Pt 1):G98-102. PubMed ID: 2578257 [TBL] [Abstract][Full Text] [Related]
5. Cholecystokinin (pancreozymin). 5. Hormonally active desamino derivative of Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2. Bodanszky M; Martinez J; Walker M; Gardner JD; Mutt V J Med Chem; 1980 Jan; 23(1):82-5. PubMed ID: 6153722 [No Abstract] [Full Text] [Related]
6. Effect of cholecystokinin variant (CCK39) on dispersed acinar cells from guinea pig pancreas. Sjodin L; Gardner JD Gastroenterology; 1977 Nov; 73(5):1015-8. PubMed ID: 198332 [TBL] [Abstract][Full Text] [Related]
7. Bioactivity of cholecystokinin analogues: CCK-8 is not more potent than CCK-33. Solomon TE; Yamada T; Elashoff J; Wood J; Beglinger C Am J Physiol; 1984 Jul; 247(1 Pt 1):G105-11. PubMed ID: 6204542 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Makovec F; Bani M; Cereda R; Chisté R; Pacini MA; Revel L; Rovati LA; Rovati LC; Setnikar I Arzneimittelforschung; 1987 Nov; 37(11):1265-8. PubMed ID: 3440035 [TBL] [Abstract][Full Text] [Related]
9. [Studies on the total synthesis of cholecystokinin-pancreozymin. Synthesis of the suitably protected fragment corresponding to the sequence 24--33 (author's transl)]. Wünsch E; Moroder L; Wilschowitz L; Göhring W; Scharf R; Gardner JD Hoppe Seylers Z Physiol Chem; 1981 Feb; 362(2):143-52. PubMed ID: 7216168 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological activity of some partially modified retro-inverso analogues of cholecystokinin. Rodriguez M; Galas MC; Lignon MF; Mendre C; Laur J; Aumelas A; Martinez J J Med Chem; 1989 Oct; 32(10):2331-9. PubMed ID: 2477546 [TBL] [Abstract][Full Text] [Related]
11. Suc-Tyr(SE)-Met-Gly-Trp-Met-Asp-beta-phenethylamide(410): a competitive antagonist of cholecystokinin-induced contractions in smooth muscles in vitro. Rakovska A; Henklein P; Milenov K; Nieber K; Oehme P Methods Find Exp Clin Pharmacol; 1987 Jul; 9(7):429-35. PubMed ID: 3683016 [TBL] [Abstract][Full Text] [Related]
12. 2-Phenylethyl ester and 2-phenylethyl amide derivative analogues of the C-terminal hepta- and octapeptide of cholecystokinin. Fulcrand P; Rodriguez M; Galas MC; Lignon MF; Laur J; Aumelas A; Martinez J Int J Pept Protein Res; 1988 Nov; 32(5):384-95. PubMed ID: 2463231 [TBL] [Abstract][Full Text] [Related]
13. [Cholecystokinin-pancreozymin synthesis. Synthesis of [28-threonine,31-norleucine]- and [28-threonine,31-leucine]cholecystokinin-pancreozymin-(25-33)-nonapeptide]. Moroder L; Wilschowitz L; Gemeiner M; Göhring W; Knof S; Scharf R; Thamm P; Gardner JD; Solomon TE; Wünsch E Hoppe Seylers Z Physiol Chem; 1981 Jul; 362(7):929-42. PubMed ID: 7275014 [TBL] [Abstract][Full Text] [Related]
14. Role of sulfate ester in influencing biologic activity of cholecystokinin-related peptides. Vinayek R; Jensen RT; Gardner JD Am J Physiol; 1987 Feb; 252(2 Pt 1):G178-81. PubMed ID: 2435164 [TBL] [Abstract][Full Text] [Related]
15. Cholecystokinin (pancreozymin). 3. Synthesis and properties of an analogue of the C-terminal heptapeptide with serine sulfate replacing tyrosine sulfate. Bodanszky M; Natarajan S; Hahne W; Gardner JD J Med Chem; 1977 Aug; 20(8):1047-50. PubMed ID: 894673 [TBL] [Abstract][Full Text] [Related]
16. The importance of the amino acid in position 27 of cholecystokinin in determining its biological activity on pancreatic acini. Gardner JD; Walker MD; Martinez J; Priestly GP; Natarajan S; Bodanszky M Biochim Biophys Acta; 1980 Jul; 630(3):323-9. PubMed ID: 6156709 [TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship studies on cholecystokinin: analogues with partial agonist activity. Galas MC; Lignon MF; Rodriguez M; Mendre C; Fulcrand P; Laur J; Martinez J Am J Physiol; 1988 Feb; 254(2 Pt 1):G176-82. PubMed ID: 2450468 [TBL] [Abstract][Full Text] [Related]
19. Sequence variation outside the "active" region of dog and rabbit cholecystokinin-58 results in bioactivity differences. Reeve JR; Liddle RA; Shively JE; Lee TD; Keire DA; Chew P; Vigna SR Pancreas; 2006 Apr; 32(3):306-13. PubMed ID: 16628087 [TBL] [Abstract][Full Text] [Related]
20. Cholecystokinic activity of N alpha-hydroxysulfonyl-[Nle28,31]CCK26-33 analogues modified at the C-terminal residue. Sugg EE; Serra M; Shook JE; Yamamura HI; Burks TF; Korc M; Hruby VJ Int J Pept Protein Res; 1988 Jun; 31(6):514-9. PubMed ID: 2457563 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]